{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:06:35Z","timestamp":1771340795690,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Regions of Southern Denmark","award":["17\/18517"],"award-info":[{"award-number":["17\/18517"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.eplepsyres.2020.106547","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T10:22:47Z","timestamp":1610101367000},"page":"106547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Risk factors of paradoxical reactions to anti-seizure medication in genetic generalized epilepsy"],"prefix":"10.1016","volume":"170","author":[{"given":"Joanna","family":"Gesche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helle","family":"Hjalgrim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Rubboli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8268-1492","authenticated-orcid":false,"given":"Christoph Patrick","family":"Beier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2020.106547_bib0005","doi-asserted-by":"crossref","DOI":"10.1097\/WNF.0b013e31825eed8c","article-title":"Levetiracetam may worsen myoclonus in patients with juvenile myoclonic epilepsy: case reports","volume":"35","author":"Babtain","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0010","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1212\/01.WNL.0000098891.76373.15","article-title":"Idiopathic generalized epilepsy and choice of antiepileptic drugs","volume":"61","author":"Benbadis","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0015","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1212\/WNL.56.10.1424-a","article-title":"Exacerbation of juvenile myoclonic epilepsy with lamotrigine","volume":"56","author":"Carrazana","year":"2001","journal-title":"Neurology"},{"issue":"46 Suppl 9","key":"10.1016\/j.eplepsyres.2020.106547_bib0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1528-1167.2005.00325.x","article-title":"Seizure aggravation in idiopathic generalized epilepsies","author":"Chaves","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0025","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/01.wnl.0000174517.21383.36","article-title":"Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies","volume":"65","author":"Crespel","year":"2005","journal-title":"Neurology"},{"issue":"28 Suppl 1","key":"10.1016\/j.eplepsyres.2020.106547_bib0030","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.yebeh.2013.01.001","article-title":"Management of juvenile myoclonic epilepsy","author":"Crespel","year":"2013","journal-title":"Epilepsy Behav.: E&B"},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0035","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.0013-9580.2004.19704.x","article-title":"Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies","volume":"45","author":"Gelisse","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0040","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.0013-9580.2004.19704.x","article-title":"Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies","volume":"45","author":"Gelisse","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0045","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1212\/WNL.55.8.1106","article-title":"Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy?","volume":"55","author":"Genton","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0050","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/ene.14142","article-title":"Epidemiology and outcome of idiopathic generalized epilepsy in adults","volume":"27","author":"Gesche","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0055","doi-asserted-by":"crossref","first-page":"e2519","DOI":"10.1212\/WNL.0000000000010644","article-title":"Patterns and prognostic markers for treatment response in generalized epilepsies","volume":"95","author":"Gesche","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0060","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00023210-200317090-00003","article-title":"Antiepileptic drug-induced pharmacodynamic aggravation of seizures","volume":"17","author":"Hirsch","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0065","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.yebeh.2012.11.051","article-title":"Consensus on diagnosis and management of JME: from founder\u2019s observations to current trends","volume":"28","author":"Kasteleijn-Nolst","year":"2013","journal-title":"Epilepsy Behav.: E&B"},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0070","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/14737159.2019.1573144","article-title":"From next-generation sequencing to targeted treatment of non-acquired epilepsies","volume":"19","author":"M\u00f8ller","year":"2019","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0080","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1059131102001723","article-title":"A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy","volume":"12","author":"Nakken","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0085","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pediatrneurol.2005.03.001","article-title":"Aggravation of epilepsy by antiepileptic drugs","volume":"33","author":"Sazgar","year":"2005","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0090","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jnnp.56.5.448","article-title":"Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures","volume":"56","author":"Schapel","year":"1993","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0095","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00115-004-1696-5","article-title":"Levetiracetam in combined therapy for focal epilepsy: experience with 80 patients","volume":"75","author":"Schulze-Bonhage","year":"2004","journal-title":"Der Nervenarzt"},{"issue":"28 Suppl 1","key":"10.1016\/j.eplepsyres.2020.106547_bib0100","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.yebeh.2012.11.042","article-title":"Neurophysiology of juvenile myoclonic epilepsy","author":"Serafini","year":"2013","journal-title":"Epilepsy Behav.: E&B"},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0105","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/j.1528-1167.2008.01585.x","article-title":"The risk of paradoxical levetiracetam effect is increased in mentally retarded patients","volume":"49","author":"Szucs","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2020.106547_bib0110","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/brain\/awl047","article-title":"Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy","volume":"129","author":"Thomas","year":"2006","journal-title":"Brain"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121120305982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121120305982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:44:15Z","timestamp":1760276655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121120305982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":22,"alternative-id":["S0920121120305982"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106547","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors of paradoxical reactions to anti-seizure medication in genetic generalized epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106547","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106547"}}